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Staphylococcus aureus is a common cause of severe bloodstream infection. We performed a systematic review to assess whether con-
sultation with infectious disease specialists decreased all-cause mortality or rate of complications of S aureus bloodstream infections.
The review also assessed parameters associated with the quality of management of the infection. We searched for eligible studies in
PubMed, Embase, Scopus, and clinical trials.gov as well as the references of included studies. We identiﬁed 22 observational studies
and 1 study protocol for a randomized trial. A meta-analysis was not performed because of the high risk of bias in the included
studies. The outcomes are reported in a narrative review. Most included studies reported survival beneﬁt, in the adjusted analysis.
Recommended management strategies were carried out signiﬁcantly more often among patients seen by an infectious disease
specialist. Trials, such as cluster-randomized controlled trials, can more validly assess the studies at low risk of bias.
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BACKGROUND
Staphylococcus aureus (S aureus) is a common cause of severe
bloodstream infection [1]. The incidence was found to be 26/
100 000 population per year, and the 30-day all-cause mortality
is approximately 20% [3]. S aureus possesses a great afﬁnity for
foreign bodies and has a propensity to produce bioﬁlm, making
patients vulnerable to infections of catheters, prosthetic joints,
heart valves, and pacemakers. They are also prone to metastatic
infections and abscess formation. S aureus bloodstream infec-
tions may result in severe sepsis with organ failure and septic
shock [4].Risk factors for acquiring S aureus bloodstream infec-
tion include older age, dialysis treatment, diabetes mellitus, and
immunosuppression [1, 5]. Factors associated with a poor prog-
nosis of the infection include older age, comorbid conditions,
severity of the infection, certain foci of infection including en-
docarditis, pneumonia, and undetermined focus, inadequate
antibiotic treatment, and nonremoval of a removable infectious
focus [3]. Echocardiography is recommended for all patients
with S aureus bacteremia [6]. A recent review paper recom-
mends that although the evidence in this ﬁeld is weak, transtho-
racic echocardiography may be adequate for patients with a low
risk of endocarditis [7].Removal of the source of infection is im-
portant because nonremoval of an intravascular device has been
associated with treatment failure [8], and a noneradicated focus
has been found to be a predictor of mortality [9]. Timing and
choice of antibiotic are important, because both delay in treat-
ment and inappropriate choice of antibiotic are associated with
decreased survival [3].
Expected Effect of the Intervention
The intervention consists of implementing infectious disease
specialist consultations for patients with S aureus bacteremia.
Current management recommendations may vary over time,
but the intervention is an attempt to implement the best avail-
able practice. Four previous articles have summarized part of
this evidence [7, 10–12]. When this article was submitted for
publication, no full systematic review of the literature regard-
ing this topic had been published; however, since then, an ar-
ticle has been published on this subject and will be discussed
under Agreements and Disagreements With Other Studies or
Reviews [13]. Our primary objective was to assess whether
consultation with an infectious disease specialist among pa-
tients with S aureus bloodstream infection decreased mortality
rates or rates of recurrence of the infection compared with
those who did not receive the intervention. We also studied
whether the intervention increased the quality of patient
management.
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METHODS
Criteria for Considering Studies for This Review
All controlled trials and prospective or retrospective observa-
tional studies on this topic were eligible for inclusion in our
study. The studies were grouped according to their design.
The consultation could occur in person or by review of patient
records. We included (1) studies comparing those receiving the
intervention with those who did not and (2) studies comparing
time periods with varying degrees of implementation of infec-
tious disease specialist consultation.
Types of Outcome Measures
The primary outcome of interest was all-cause mortality within
7, 30, or 90 days of onset of infection as well as in-hospital mor-
tality. Secondary outcomes included recurrence of bacteremia as
well as parameters indicating quality of patient management.
The latter included rates of examination by echocardiography,
frequency of follow-up blood cultures, frequency of detection of
focus of infection including endocarditis and metastatic infec-
tion, whether a removable focus was removed or drained, and
adequacy of antibiotic treatment.
Search Methods for Identiﬁcation of Studies
PubMed was searched from 1944 through August 26, 2015 with
a combination of medical subject heading (MeSH) and free text
terms. The search included terms to identify S aureus, the pres-
ence of bloodstream infection, and the presence of infectious
disease specialist consultation. Embase and Scopus were
searched through August 26, 2015. The detailed search strategy
is provided in the Supplementary Material. Clinical trials.gov
was searched for completed or ongoing randomized trials. Ref-
erence lists of all included studies were searched. Studies in all
languages were eligible for inclusion in the review. A librarian
experienced with literature search for systematic reviews was
consulted. The identiﬁed articles were screened for relevance
based on title or abstract. For studies that met the inclusion cri-
teria, or cases in which the relevance was not clear, the full text
was studied.
Assessment of Risk of Bias in Included Studies
Risk of bias was assessed using the Newcastle-Ottawa scale for
assessing the quality of nonrandomized studies. This scale was
subdivided into 3 categories, which were evaluated based on the
selection of the exposed and nonexposed groups, the compara-
bility of the groups, and the ascertainment of exposure or out-
come. A star was awarded if the exposed cohort in the study was
truly or somewhat representative of the cohort with this disease
in the community, if the nonexposed cohort was drawn from
the same community as the exposed cohort, if the outcome
was assessed by record linkage or structured interview, and if
there was demonstration that the outcome of interest was not
present at the start of the study. For comparability, a star was
given for adjustment for the most important confounding
factor, and an additional star was given for adjustment of any
other factor. For outcome, a star was awarded if the outcome
measure was ascertained blindly or by independent record link-
age, if the follow up was long enough for the outcome to occur,
and if there was little loss to follow up. A study was awarded a
maximum of 4 stars for selection, 2 stars for comparability, and
3 stars for outcome ascertainment [14]. All studies were as-
sessed by 2 authors, the ﬁrst author and one coauthor. Any dis-
agreement regarding the assessment was resolved by discussion
within the group. Particular attention was paid to selection bias
and confounding and how these were identiﬁed and adjusted.
Measures of Treatment Effect
The Revman data analysis tool, developed by the Cochrane Col-
laboration, was used for summarizing the outcomes. Data were
entered in outcome tables, and odds ratios (ORs) with 95% con-
ﬁdence intervals (CIs) were calculated by the Mantel-Haenzsel
method. For adjusted analysis, the log OR and standard error
were entered, and ORs were calculated by inverse variance
methods. All results were reported for those receiving the inter-
vention compared with those who did not. If the included study
reported results for the control group compared with the inter-
vention group, the results were inversed for the purpose of this
review so that the magnitude of the results from all studies and
subgroup analyses could be compared. A pooled analysis was
not performed because of the high risk of bias in the included
studies, irrespective of the statistical measures of heterogeneity.
The estimates of treatment effect and CIs for each study were
displayed by forest plots, and a funnel plot was used to assess
the existence of publication bias.
RESULTS
Results of the Search
The ﬁnal database search was conducted on August 26, 2015
and revealed 1785 records identiﬁed after removal of duplicates.
In addition, 18 studies were identiﬁed from the references of in-
cluded studies. In total, 1803 record abstracts or titles were
screened and 1741 were excluded during the screening. Sixty-
one full-text articles and 1 study protocol were assessed, and
22 studies and 1 study protocol met the inclusion criteria for
this systematic review. Thirty-nine studies were excluded be-
cause the intervention did not specify information for S aureus
or primary outcomes of interest for this review (Figure 1).
Among the 22 studies included, 16 assessed the effect of in-
fectious disease consultation by comparing those receiving the
consultation with those who did not [10, 15–28] and whether
the advice given was heeded or not [8]. Five studies compared
time periods in which an intervention with infectious disease
consultation was offered or implemented on a mandatory
basis to a time period in which this intervention was not system-
atically offered [29–33], and 1 study compared early and late
time periods after implementation of mandatory infectious
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disease consultation for patients with S aureus bloodstream
infection [34] (Table 1).
The studies were published between 1998 and 2015 and
included between 18 and 847 subjects. In total, there were data
on 6927 patients. Eight studies were carried out in Europe [17,
18, 25, 27, 30–33], 3 studies were carried out in Asia [21, 23, 34],
1 study was carried out in Australia [22], and 10 studies were car-
ried out in North America [8, 10, 15, 16, 19, 20, 24, 26, 28, 29].
Risk of Bias in Included Studies
All of the included studies are observational and as such are at an
increased risk of bias, mainly selection bias. Some studies report-
ed incomplete follow-up data [18, 27, 34], which make their out-
come assessment somewhat less robust. However, most studies
included all patients meeting deﬁned criteria consecutively over
a given period, so that the overall outcome assessments were
deemed to be reliable. Most studies excluded those who died
Figure 1. Literature search flowchart. Abbreviation: SAB, Staphylococcus aureus bloodstream infection.
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before the blood culture results were available, or where care was
withdrawn, because they would not have been able to beneﬁt
from the intervention. In all the studies where baseline variables
were displayed, there were differences in factors that could be as-
sociated with the risk of mortality between the intervention
groups (Supplementary Table 1). Sixteen studies provided effect
estimates adjusted for potential confounding factors [10, 15–21,
24, 25, 27–30, 33, 34], and 6 studies provided unadjusted effect es-
timates only [8, 22, 23, 26, 31, 32]. The degree of adjustment of all
important confounders differed between the studies (Supplemen-
tary Table 1). The details of the Newcastle-Ottawa score are pre-
sented in Table 2. A funnel plot of studies assessing unadjusted
outcomes did not show any sign of publication bias (Figure 2).
Effects of Interventions
All-Cause Mortality and Recurrence Rates
Most studies comparing those who received the intervention
with those who did not reported a clear beneﬁt of infectious
disease consultation in unadjusted analysis for all-cause mor-
tality after 1 week, 4 weeks, and in-hospital. The effect was
less clear for 12-week mortality, with 2 studies showing a ben-
eﬁt [18, 25] and 2 studies showing no signiﬁcant beneﬁt [8, 10]
(Figure 3). Eleven studies provided adjusted estimates of 1 or
multiple of these outcomes: 1 study showed beneﬁt after 1
week (OR = 0.03; 95% CI, .00–.26) [27]; 2 studies showed ben-
eﬁt after 4 weeks (OR = 0.44 [95% CI, .22–.88] [20] and
OR = 0.27 [95% CI, .10–.75]) [27]; and 2 studies suggested a
beneﬁt, although the statistical evidence for this effect was in-
sufﬁcient (OR = 0.23 [95% CI, 0.02–2.56] [21] and OR = 0.71
[95% CI, .35–1.48]) [16]. Three studies showed beneﬁt in ad-
justed analysis after 12 weeks [18, 24, 25], with OR from 0.28
(95% CI, .13–.62) [25] to 0.50 (95% CI, .29–.87) [18], and 1
study suggested a beneﬁt, although this was not statistically
signiﬁcant (OR = 0.67; 95% CI, .14–3.22) [10]. Most studies
that assessed in-hospital mortality showed beneﬁt in adjusted
analysis with OR estimates ranging from 0.45 (95% CI,
Table 1. Description of Included Studies
Study Setting Study Design Intervention/Control
Number of Patients
(Intervention/Control)
Lundberg et al [15] 900-bed teaching hospital Matched retrospective cohort study IDC/No IDC 18 (9/9)
Fowler et al [8] University medical center Prospective cohort study Advice from IDC heeded/not heeded 244 (112/132)
Mylotte and Tayara [16] 300-bed public university
affiliated hospital
Retrospective cohort study IDC/No IDC 281 (100/181)
Kaech et al [17] 800-bed university hospital Retrospective cohort study IDC/No IDC 308
Jenkins et al [29] 400-bed teaching hospital Retrospective cohort study Preintervention period/Intervention
period
234 (100/134)
Rieg et al [18] 1600-bed tertiary care
center
Cohort study. First period retrospective,
second period prospective.
IDC/No IDC 521 (350/171)
Lahey et al [19] Tertiary care hospital Prospective cohort study IDC/No IDC 240 (122/118)
Nagao et al [34] 1240-bed tertiary hospital Retrospective cohort study Early and late period after mandatory
IDC was implemented
346 (194/152)
Honda et al [20] Large tertiary care hospital Prospective cohort study IDC/No IDC 341 (111/230)
Choi et al [21] Hospital with <400 beds Retrospective cohort study IDC/No IDC 100 (42/58)
Robinson et al [22] 955-bed tertiary referral
center
Retrospective cohort study IDC/No IDC 599 (162/437)
Isobe et al [23] University hospital Retrospective cohort study IDC/No IDC 115 (28/87)
Pragman et al [10] 279-bed medical center Retrospective cohort study IDC/No IDC 233 (179/54)
Pastagia et al [24] 1171-bed tertiary care
center
Retrospective cohort study IDC/No IDC 699 (461/238)
Forsblom et al [25] University hospital Retrospective cohort study IDC/telephone consultation only/No
IDC
342 (245/62/35)
Lopez-Cortes et al [30] 12 tertiary hospitals Quazi-experimental study Preintervention period/Intervention
period.
508 (221/287)
Fries et al [26] Tertiary care hospital Retrospective cohort study IDC/No IDC 177 (142/35)
Tissot et al [27] 1000-bed tertiary care
center
Retrospective cohort study IDC/No IDC 148 (118/30)
Borde et al [31] 200-bed community
hospital
Cohort study. First period retrospective,
second period prospective.
Preintervention period/Intervention
period
59 (20/39)
Saunderson et al [32] Large acute university
hospital
Cohort study. First period retrospective,
second period prospective.
Preintervention period/Intervention
period
63 (35/28)
Bai et al [28] 6 academic and
community hospitals
Retrospective cohort study IDC/No IDC 847 (506/341)
Saunderson et al [33] Teaching hospital Cohort study. First period retrospective,
second period prospective.
Preintervention period/Intervention
period.
477 (183/294)
Abbreviation: IDC, infectious disease consultation.
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.22–.93) [19] to 0.72 (95% CI, .52–.99) [28], except for Kaech
[17]. Bai [28] assessed in-hospital mortality after 12 weeks
both by a propensity score-matched analysis and by a thor-
oughly adjusted logistic regression model and showed a beneﬁt
of the intervention (hazard ratio = 0.72; 95% CI, .52–.99)
(Figure 4).
Among studies comparing 2 time periods, 6 provided unad-
justed measures and 3 provided adjusted measures of all-cause
mortality. In unadjusted analysis, most studies showed reduced
or borderline reduced all-cause 4-week mortality [30, 33, 34], ex-
cept for the study on pediatric patients by Saunderson [32]. In
adjusted analysis, Lopez-Cortes [30] showed beneﬁt for 4-week
mortality (OR = 0.59; 95% CI, .36–.97), and 2 studies showed
borderline statistical evidence for beneﬁt with OR = 0.60 (95%
CI, .35–1.03) [34] and OR = 0.62 (95% CI, .37–1.04) [33], re-
spectively. For 12-week mortality, 3 studies did not show a
clear beneﬁt in the unadjusted analysis [29, 30, 32] (Figure 3),
whereas 1 study showed a beneﬁt in the intervention period
in unadjusted analysis with OR = 0.62 (95% CI, .40–.96) but
not in adjusted analysis (OR = 0.85; 95% CI, .57–1.27) [33]
(Figure 4).
Eight studies examined the recurrence of bloodstream infec-
tion within 12 weeks. In the study by Fowler et al [8], there was
less recurrence among those who heeded the advice of the in-
fectious disease consultant compared with those who did not
(OR = 0.28; 95% CI, .10–.77); other studies were inconclusive
(OR = 0.22 [95% CI, .04–1.23] [25] and OR = 1.29 [95% CI,
.42–4.02]) [18] (Figure 3). One study examined the adjusted
risk of 12-week relapse and suggested a protective effect of
the intervention (OR = 0.33; 95% CI, .10–1.08) [10] (Figure 4).
Patient Management Strategies
The intervention led to increased rates of examination with
echocardiography and an increased rate of acquisition of repeat
blood cultures in most studies. There was also an increase in de-
tection of metastatic complications and focus of infection. Stud-
ies that assessed adequacy of choice and timing of antibiotic
treatment reported a positive effect of the intervention. The
effect was less clear when it came to removal of a removable
infectious focus, with some studies reporting increased rates
and some not showing a clear effect (Figure 5).
DISCUSSION
Summary of Main Results
Most studies comparing those who received infectious disease
consultation with those who did not showed beneﬁt on all-
cause mortality in unadjusted analysis and many also in adjust-
ed analysis, with varying degree of adjustment for confounding
variables. At least 1 study with very thorough adjustment for
covariates showed beneﬁt of the intervention [28].
Among studies comparing time periods with and without
mandatory infectious disease consultation, most studies showed
beneﬁt after 4 weeks, but a less clear effect after 12 weeks. Due
to the design of these studies, other events having an effect on
mortality may have occurred at the same time as the implemen-
tation of mandatory infectious disease consultation so that the
effect of the program itself is less discernable. On the other
hand, these studies analyze the entire population with S aureus
bloodstream infection, and they may be more likely to reﬂect
the overall effect of the intervention. The reason why there is
a difference in effect on 4-week and 12-week mortality in stud-
ies comparing time periods could be because the outcome at 4
weeks is more likely to reﬂect mortality secondary to the infec-
tion, whereas 12-week mortality may also reﬂect the severity of
underlying conditions. None of the included studies reported
data which indicated that the intervention was harmful for
patients.
The included studies detected an increase in quality of the
management of patients with S aureus bloodstream infections.
Data from observational studies show that these management
strategies have been shown to increase the success rates of
Table 2. Summary of the Newcastle-Ottawa Score of Included Studiesa
Article Selection Comparability Outcome
Lundberg et al [15] **** ** ***
Fowler et al [8]b **** ***
Mylotte and Tayara [16] **** ** ***
Kaech et al [17] **** ** ***
Jenkins et al [29]c *** ** ***
Rieg et al [18]d **** ** **
Lahey et al [19] **** ** ***
Honda et al [20] **** ** ***
Choi et al [21] **** ** ***
Robinson et al [22] **** ***
Isobe et al [23] **** ***
Pragman et al [10] **** ** **
Pastagia et al [24] **** ** **
Forsblom et al [25] **** ** ***
Lopez-Cortes et al [30]c *** ** ***
Fries et al [26] **** **
Tissot et al [27] **** ** ***
Borde et al [31] *** ***
Saunderson et al [32]c *** ***
Bai et al [28] **** ** ***
Saunderson et al [33]c *** ** ***
a Content of the Newcastle-Ottawa scale: selection is graded based on representativeness
of the exposed cohort, selection of the nonexposed cohort, ascertainment of exposure, and
demonstration that the outcome of interest was not present at the start of the study.
Comparability refers to control of cofactors with 1 star for adjustment of the most
important cofactor and an additional star for adjustment for additional cofactors. Outcome
refers to how the outcome was assessed, if the follow-up time was long enough, and
whether it was complete. A study can be awarded a maximum of 4 stars for selection, 2
stars for comparability, and 3 stars for outcome ascertainment.
b Adjusted analysis was reported to have been performed, but results are not included in the
article.
c Compares different time periods: the exposed cohort is from the same community but not
the same time, and as such the study has not been awarded a star in question 2 under
selection (not fully comparable communities).
d Ninety patients lost to follow up for 90-day mortality.
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treatment [3, 9, 35]. The increase in detection of complications
such as endocarditis and metastatic infection could be due to a
higher proportion of high-risk patients being referred to a spe-
cialist. However, increased rates of examination with echocar-
diography have also led to increased rates of detection of
endocarditis in patients who exhibited no speciﬁc clinical signs
or symptoms [36].Moreover, this increase was also noted in stud-
ies comparing time periods before and after implementation of
routine consultation, which supports that the increase reported
is associated with an increase in detection [29].
Overall Completeness and Applicability of Evidence
Most included studies were carried out at larger tertiary referral
centers or university hospitals, but some were from smaller hos-
pitals. The studies were conducted in North America, Europe,
Asia, and Australia, and as such they provided a fairly good rep-
resentation of the situation in many industrialized countries. The
studies themselves were heterogeneous in their recruitment, size
of the intervention groups, types and timing of outcomes as-
sessed, and how potential confounders were adjusted in the anal-
ysis. This is a cause for concern regarding the overall robustness
of the results and the true effect of the intervention. It is unclear
howmuch of a pooled estimate of such studies is due to the actual
effect of the intervention and how much is due to the baseline
difference in mortality risk between those who received the inter-
vention and those who did not. On one hand, in some studies,
patients with an ultimately or rapidly fatal disease or those resid-
ing in a nursing home were underrepresented among those being
seen by the infectious disease specialist. These factors may affect
the outcome estimate in favor of the intervention, even if the in-
tervention is not truly beneﬁcial. On the other hand, in some
studies, those receiving the intervention had indicators of more
severe disease, as indicated by admissions to the intensive care
unit. This could affect the outcome estimate in favor of the non-
exposed group, although the intervention was actually beneﬁcial.
For this reason, we chose not to meta-analyze the data and opted
instead to summarize the ﬁndings of these studies and describe
their strengths and weaknesses.
One randomized controlled trial for this intervention is reg-
istered (clinical trials.gov identiﬁer NCT00622882), and if the
study is completed it may give a more robust estimate of its
overall effect. In general, it can be problematic to perform
Figure 2. Funnel plot of unadjusted all-cause mortality and recurrence of studies comparing infectious disease consultation (IDC) to no IDC. Abbreviations: OR, odds ratio; SE,
standard error.
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randomized trials with no specialist consultation because the
risk of this suboptimal management can cause harm to patients.
The study in question was registered in 2008, before many of the
studies referenced in this review were conducted, so the un-
certainty about the beneﬁt of the intervention was more
pronounced. However, one approach for currently studying
Figure 3. Unadjusted outcome analysis for mortality and recurrence. Abbreviations: CI, confidence interval; IDC, infectious disease consultation.
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this clinical intervention could be to randomize patients to
mandatory specialist consultation rather than referral for consul-
tation with a specialist, at the physician’s discretion. Cluster-
randomized trials at the institution level would be one way of
performing such a trial, avoiding cross-contamination of the
intervention within an institution.
There are limitations to our study. The literature search was
carried out with help from a qualiﬁed searcher, but the prima-
ry screening of abstracts and papers was carried out by 1
author, and, as such, there is a risk of overlooking papers
and introducing selection bias. However, we searched 3 data-
bases in addition to the references of all included studies, and
when there was doubt about the inclusion criteria, it was dis-
cussed among the coauthors. In addition, the included papers
were reviewed by experts in epidemiology and infectious dis-
eases. We chose to use the Newcastle-Ottawa scale to assess
the quality of the studies, because this reveals more details
than the Grade system, where all of the included studies
Figure 4. Adjusted outcome analysis for mortality and recurrence. Abbreviations: APS, acute physiology score; CCI, Charlson comorbidity index; CI, confidence interval; ICU,
intensive care unit; IDC, infectious disease consultation; MRSA, methicillin-resistant Staphylococcus aureus; SE, standard error.
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would be classiﬁed as low or very low quality because of the
study design. However, the Newcastle-Ottawa scale may not
be optimal for assessing clinical observational studies, and it
may not be sufﬁciently sensitive to detect subtle but important
differences in quality between the included studies [37, 38]. In
general, there is a need for improved instruments for assessing
the quality of observational studies included in systematic re-
views [39].
Agreements and Disagreements With Other Studies or Reviews
Another systematic review on the same topic was published by
Vogel et al [13]while this article was under review. The selection
of papers is quite similar, and the conclusion regarding the
beneﬁcial effect of the intervention is also similar. Our
approaches differ in that we have chosen not to conduct a
meta-analysis of these studies because of the methodological
differences and uncertainty about the true causal effect, to
avoid producing a biased pooled estimate. Some studies have
discussed a subset of these papers as part of the discussion of
their own research or as part of narrative reviews [7, 10–12].
All of these reviews emphasized the improved management of
these patients by the intervention, and some recommended that
the intervention should be offered to all patients with S aureus
bloodstream infection [7, 10].
CONCLUSIONS
Infectious disease specialist consultation for patients with
S aureus bloodstream infection is associated with improved
patient management and, plausibly, improved survival. Because
of the inherent difﬁculties of assessing the true effect of inter-
ventions in observational studies, more robust methods, such
as cluster-randomized controlled trials at the institution level,
should be developed.
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